BioWorld

Feb. 15, 2005

View Archived Issues

Encysive Stock Moves Up 12 Percent On Thelin Data

Encysive Pharmaceuticals Inc. plans to file a new drug application in April based on pivotal Phase III data showing that Thelin met its primary endpoint in pulmonary arterial hypertension. (BioWorld Today) Read More

Discovery Laboratories Gets Surfaxin Approvable Letter

Read More

ConjuChem Raises C$21.7M For Upcoming DAC Studies

Read More

Accentia Files For $86M IPO To Fund Trials, Pay Off Debt

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More